Press release
Pipeline Analysis on Neutropenia with Therapeutic Development Reviewed for H1 2017
Market Research HUB
Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1068019
According to the researchers, fever during chemotherapy-induced neutropenia may be the only symptom of a severe underlying infection, because signs and symptoms of inflammation typically are lessened. Physicians must be keenly aware of the infection risks, diagnostic methods, and antimicrobial therapies required for management of febrile patients through the neutropenic period. Accordingly, several approaches to diagnose and treatment for the disease are in process. This report also provides comprehensive information on the therapeutics under development for Neutropenia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
In the first part, the report explains the disease overview along with its sign and symptoms, causes etc. Neutropenia is a blood disorder characterized by a lack of neutrophils, a type of white blood cell and vital for fighting off pathogens, particularly bacterial infections. Neutropenia itself does not present any symptoms. Often it is identified during routine blood tests or tests for other illness. Major signs of this infection are sweating, high fever or low temperature, abdominal pains, sore throat, changes in mental state, mucositis and others. The most serious concern with neutropenia is constricting an infection, which can easily spread throughout the body without adequate neutrophil numbers to control it.
Further, the report talks about the therapeutic development, pipeline overview and products under development by companies. Major companies that are currently involved in the therapeutic development are Adello Biologics LLC, BeyondSpring Pharmaceuticals Inc, Cleveland BioLabs Inc, Apotex Inc, Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., Arven Ilac, Eurofarma Laboratorios SA, Cellerant Therapeutics Inc, Sandoz International GmbH, Coherus BioSciences Inc, Prolong Pharmaceuticals LLC, Ligand Pharmaceuticals Inc, Mycenax Biotech Inc, Lupin Ltd., Richter Gedeon Nyrt and USV Pvt. Ltd. The report also enlists all the major and minor projects of these companies. With the above information, this pipeline guide helps in identifying developing players in the market and their portfolios enhance decision-making capabilities and help to build effective counter tactics to gain competitive advantage.
Browse Full Report With TOC: http://www.marketresearchhub.com/report/neutropenia-pipeline-review-h1-2017-report.html
Drug Profiles mentioned in this research report are ACN-8337, plinabulin, CBLB-612, EC-18, filgrastim, LG-7455, pegfilgrastim, pegfilgrastim (recombinant), romyelocel-L, ST-7 and tamibarotene.
About Market Research Hub:
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
Contact Us
90 State Street,
Albany, NY 12207,
United States
Toll Free: 866-997-4948 (US-Canada)
Tel: +1-518-621-2074
Email: press@marketresearchhub.com
Follow us on:
Twitter: twitter.com/MktResearchHub
LinkedIn: www.linkedin.com/company/market-research-hub
Facebook: www.facebook.com/MarketResearchHub/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pipeline Analysis on Neutropenia with Therapeutic Development Reviewed for H1 2017 here
News-ID: 539965 • Views: …
More Releases from Medical Industry Research Reports - MRH
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Global Clinical Trials …
Market Research Hub (MRH) has recently broadcasted a new study to its broad research portfolio, which is titled as “Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Global Clinical Trials Review, H1, 2017”, provides an overview of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) clinical trials scenario. This report provides top line data relating to the clinical trials on Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Report includes an overview of trial numbers and their average enrollment…
Chronic Kidney Disease (Chronic Renal Failure) Global Clinical Trials Reviewed, …
Market Research Hub (MRH) has recently broadcasted a new study to its broad research portfolio, which is titled as “Chronic Kidney Disease (Chronic Renal Failure) Global Clinical Trials Review, H1, 2017”, provides an overview of Chronic Kidney Disease (Chronic Renal Failure) clinical trials scenario. This report provides top line data relating to the clinical trials on Chronic Kidney Disease (Chronic Renal Failure). Report includes an overview of trial numbers and…
Chronic Liver Disease Global Clinical Trials Reviewed H1 – 2017: Pharmaceutica …
Market Research Hub (MRH) has recently broadcasted a new study to its broad research portfolio, which is titled as “Chronic Liver Disease Global Clinical Trials Review, H1, 2017”, provides an overview of Chronic Liver Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Chronic Liver Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the…
Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review H1 – 2017: Ma …
Market Research Hub (MRH) has recently broadcasted a new study to its broad research portfolio, which is titled as “Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2017”, provides an overview of Chronic Lymphocytic Leukemia (CLL) clinical trials scenario. This report provides top line data relating to the clinical trials on Chronic Lymphocytic Leukemia (CLL). Report includes an overview of trial numbers and their average enrollment in top countries…
More Releases for Neutropenia
Global Neutropenia Market Poised for Significant Growth
Full Report: https://www.alliedmarketresearch.com/neutropenia-treatment-market-A06298
The global neutropenia market is witnessing notable expansion, driven by rising cancer prevalence, innovative treatment developments, and increasing adoption of biosimilars. According to industry reports, the market was valued at $12.6 billion in 2019 and is projected to reach $19.3 billion by 2027, growing at a CAGR of 5.4%.
Get a Sample Copy of this Report: https://www.alliedmarketresearch.com/request-sample/A06298
Understanding Neutropenia
Neutropenia is a medical condition characterized by a deficiency of neutrophils, a…
Shaping the Neutropenia Biologic Drug Treatment Market in 2025: Advancing Neutro …
How Big Is the Neutropenia Biologic Drug Treatment Market Expected to Be, and What Will Its Growth Rate Be?
The market size for biologic drug treatment of neutropenia has seen robust growth in recent times. The market, which is projected to escalate from $13.22 billion in 2024, is expected to reach $14.08 billion in 2025, representing a compound annual growth rate (CAGR) of 6.5%. Factors such as improved market access and…
Shaping the Neutropenia Biologic Drug Treatment Market in 2025: Advancing Neutro …
How Big Is the Neutropenia Biologic Drug Treatment Market Expected to Be, and What Will Its Growth Rate Be?
The market size for biologic drug treatment of neutropenia has seen robust growth in recent times. The market, which is projected to escalate from $13.22 billion in 2024, is expected to reach $14.08 billion in 2025, representing a compound annual growth rate (CAGR) of 6.5%. Factors such as improved market access and…
Shaping the Neutropenia Biologic Drug Treatment Market in 2025: Advancing Neutro …
How Big Is the Neutropenia Biologic Drug Treatment Market Expected to Be, and What Will Its Growth Rate Be?
The market size for biologic drug treatment of neutropenia has seen robust growth in recent times. The market, which is projected to escalate from $13.22 billion in 2024, is expected to reach $14.08 billion in 2025, representing a compound annual growth rate (CAGR) of 6.5%. Factors such as improved market access and…
Biologic Drug Treatments for Neutropenia: Market Trends 2024
"The Business Research Company recently released a comprehensive report on the Global Neutropenia Biologic Drug Treatment Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free…
"Revolutionary Advances in Neutropenia Treatment: A Booming Market Opportunity"
𝐓𝐡𝐞 𝐠𝐥𝐨𝐛𝐚𝐥 𝐧𝐞𝐮𝐭𝐫𝐨𝐩𝐞𝐧𝐢𝐚 𝐦𝐚𝐫𝐤𝐞𝐭 𝐬𝐢𝐳𝐞 𝐰𝐚𝐬 𝐯𝐚𝐥𝐮𝐞𝐝 𝐚𝐭 $12,602.5 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 2019, 𝐚𝐧𝐝 𝐢𝐬 𝐞𝐱𝐩𝐞𝐜𝐭𝐞𝐝 𝐭𝐨 𝐫𝐞𝐚𝐜𝐡 $19,303.1 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 2027, 𝐰𝐢𝐭𝐡 𝐚 𝐂𝐀𝐆𝐑 𝐨𝐟 5.4% 𝐝𝐮𝐫𝐢𝐧𝐠 𝐭𝐡𝐞 𝐟𝐨𝐫𝐞𝐜𝐚𝐬𝐭 𝐩𝐞𝐫𝐢𝐨𝐝.
Neutropenia is a condition characterized by a low count of neutrophils, a type of white blood cell that helps fight infections. The treatment of neutropenia depends on the underlying cause and severity of the condition. Here are some common treatments…
